The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability resulting in approximately three times greater potency than IGF-1, with a significantly longer half-life of about 2030 hours relative to IGF-1s half-life of about 1215 hours
Side effects affect the stomach or intestines but differ depending on the specific drug and dosage
While Faubions initial research suggests that combining MHT and a GLP-1 may help with weight loss, more studies need to be done
The gut-brain axis mechanism regulating insulin secretion and sensitivity involves the vagus nerve
GLP-1 is cut from a precursor protein called proglucagon, encoded by the GCG gene
A high safety profile agrees with a Phase 1 clinical trial of GBS-01, an orally administered drug rich in arctigenin, whereby no dose-limiting toxicities were observed [82]